The Robustness of Pathway Analysis in Identifying Potential Drug Targets in Non-Small Cell Lung Carcinoma

Overview

Journal Microarrays (Basel)

Date 2016 Sep 8

PMID 27600345

Citations 1

Authors

Andrew Dalby

Ian Bailey

Affiliations

Soon will be listed here.

Abstract

The identification of genes responsible for causing cancers from gene expression data has had varied success. Often the genes identified depend on the methods used for detecting expression patterns, or on the ways that the data had been normalized and filtered. The use of gene set enrichment analysis is one way to introduce biological information in order to improve the detection of differentially expressed genes and pathways. In this paper we show that the use of network models while still subject to the problems of normalization is a more robust method for detecting pathways that are differentially overrepresented in lung cancer data. Such differences may provide opportunities for novel therapeutics. In addition, we present evidence that non-small cell lung carcinoma is not a series of homogeneous diseases; rather that there is a heterogeny within the genotype which defies phenotype classification. This diversity helps to explain the lack of progress in developing therapies against non-small cell carcinoma and suggests that drug development may consider multiple pathways as treatment targets.

Citing Articles

Predicting and affecting response to cancer therapy based on pathway-level biomarkers.

Ben-Hamo R, Berger A, Gavert N, Miller M, Pines G, Oren R Nat Commun. 2020; 11(1):3296.

PMID: 32620799 PMC: 7335104. DOI: 10.1038/s41467-020-17090-y.

References

Golub T, Slonim D, Tamayo P, Huard C, Gaasenbeek M, Mesirov J . Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999; 286(5439):531-7. DOI: 10.1126/science.286.5439.531. View

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M . Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun. 2001; 270(2):400-5. DOI: 10.1006/bbrc.2000.2436. View

Polakis P . Wnt signaling and cancer. Genes Dev. 2000; 14(15):1837-51. View

Smits V, Klompmaker R, Arnaud L, Rijksen G, Nigg E, Medema R . Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol. 2000; 2(9):672-6. DOI: 10.1038/35023629. View

Bhattacharjee A, Richards W, Staunton J, Li C, Monti S, Vasa P . Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001; 98(24):13790-5. PMC: 61120. DOI: 10.1073/pnas.191502998. View

Brambilla E, Travis W, Colby T, Corrin B, Shimosato Y . The new World Health Organization classification of lung tumours. Eur Respir J. 2002; 18(6):1059-68. DOI: 10.1183/09031936.01.00275301. View

van Noort M, Clevers H . TCF transcription factors, mediators of Wnt-signaling in development and cancer. Dev Biol. 2002; 244(1):1-8. DOI: 10.1006/dbio.2001.0566. View

van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A . The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002; 111(2):241-50. DOI: 10.1016/s0092-8674(02)01014-0. View

10.

Churchill G . Fundamentals of experimental design for cDNA microarrays. Nat Genet. 2002; 32 Suppl:490-5. DOI: 10.1038/ng1031. View

11.

Sahai E, Marshall C . RHO-GTPases and cancer. Nat Rev Cancer. 2003; 2(2):133-42. DOI: 10.1038/nrc725. View

12.

Cho W, Yip T, Yip C, Yip V, Thulasiraman V, Ngan R . Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res. 2004; 10(1 Pt 1):43-52. DOI: 10.1158/1078-0432.ccr-0413-3. View

13.

Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S . Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5(10):R80. PMC: 545600. DOI: 10.1186/gb-2004-5-10-r80. View

14.

Kendziorski C, Irizarry R, Chen K, Haag J, Gould M . On the utility of pooling biological samples in microarray experiments. Proc Natl Acad Sci U S A. 2005; 102(12):4252-7. PMC: 552978. DOI: 10.1073/pnas.0500607102. View

15.

Reya T, Clevers H . Wnt signalling in stem cells and cancer. Nature. 2005; 434(7035):843-50. DOI: 10.1038/nature03319. View

16.

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

17.

Allison D, Cui X, Page G, Sabripour M . Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet. 2005; 7(1):55-65. DOI: 10.1038/nrg1749. View

18.

Strebhardt K, Ullrich A . Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006; 6(4):321-30. DOI: 10.1038/nrc1841. View

19.

Herman-Antosiewicz A, Stan S, Hahm E, Xiao D, Singh S . Activation of a novel ataxia-telangiectasia mutated and Rad3 related/checkpoint kinase 1-dependent prometaphase checkpoint in cancer cells by diallyl trisulfide, a promising cancer chemopreventive constituent of processed garlic. Mol Cancer Ther. 2007; 6(4):1249-61. DOI: 10.1158/1535-7163.MCT-06-0477. View

20.

Wilsker D, Bunz F . Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival. Mol Cancer Ther. 2007; 6(4):1406-13. DOI: 10.1158/1535-7163.MCT-06-0679. View